Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu...(chemotherapy-induced nausea ...),Health

and vomiting (CINV) associated

with cisplatin- or anthracycline

plus cyclophosphamide-based

regimens: Results of a Phase III

trial in Japanese patients

ALOXI(R) Palonosetron (PALO), administered Accepted for

(palonosetron orally or intravenously (IV), publication

HCl) plus dexamethasone for prevention only.

of chemotherapy-induced nausea

and vomiting (CINV)

GLIADEL(R) Wafer Treatment of Adults with Newly Accepted for

(polifeprosan 20 Diagnosed Glioblastoma publication

with carmustine Multiforme or Anaplastic only.

implant) Astrocytoma with Surgery, Gliadel

Wafers and Limited Field

Radiation Plus Concomitant

Temozolomide Followed by

Adjuvant Temozolomide

Eisai began its oncology research program in 1987, discovering several small molecules that are in development as chemotherapeutic agents. In addition to its in-house oncology research and development (R&D) program, Eisai made three strategic acquisitions to establish a solid business infrastructure and enter the U.S. oncology market.

In October 2006, Eisai acquired four products mainly for the treatment of cutaneous T-cell lymphoma, as well as an oncology specialty sales force from Ligand Pharmaceuticals. This provided Eisai with an initial commercial infrastructure for oncology products. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired MGI PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial ca
'/>"/>